Related Experiment Video
Updated: Mar 1, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Role of Parenteral Agents in Percutaneous Coronary Intervention for Stable Patients
David A Burke1, Duane S Pinto1
1Division of Cardiovascular Medicine, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Deaconess Road, Palmer 415, Boston, MA 02215, USA.
Insights
Selecting the best anticoagulation and antiplatelet medications for percutaneous coronary intervention (PCI) requires balancing bleeding and ischemic risks. Further research is needed on newer drug combinations to optimize patient outcomes.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Percutaneous coronary intervention (PCI) commonly involves anticoagulation and antiplatelet therapy.
- Numerous anticoagulant and antiplatelet agents are available, complicating treatment selection.
Purpose of the Study:
- To review current data on anticoagulant and antiplatelet medications used in PCI.
- To summarize guidelines for selecting optimal medical strategies based on individual patient risks.
Main Methods:
- Literature review of existing data on anticoagulant and antiplatelet therapies for PCI.
- Analysis of benefits and limitations of various drug classes.
- Summary of current clinical guidelines.
Main Results:
- Current strategies involve balancing ischemic and bleeding risks in patients undergoing PCI.
- The optimal pairing of newer antiplatelet and anticoagulant agents requires further investigation.
Conclusions:
- Individualized assessment of bleeding and ischemic risk is crucial for selecting PCI pharmacotherapy.
- Ongoing research is necessary to understand the impact of novel drug combinations on PCI complications.
Abstract:
Numerous agents are available for anticoagulation during percutaneous coronary intervention (PCI), and various antiplatelet agents are also used. With all of the medications available, an assessment must be made regarding the ischemic risk and risk of bleeding for an individual patient during elective PCI when selecting the optimal medical strategy to support PCI. Whether new antiplatelet medications will enhance or reduce complications when paired with various newer anticoagulant agents requires further investigation. This article summarizes existing data examining the benefits and limitations of the various anticoagulant and antiplatelet medications, and summarizes guidelines for their use.
More Related Videos
06:39Novel Percutaneous Approach for Deployment of 3D Printed Coronary Stenosis Implants in Swine Models of Ischemic Heart Disease
Published on: February 18, 2020
06:10Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Published on: June 12, 2021
Related Concept Videos
Coronary Artery Disease V: Interprofessional Care
Peripheral Artery Disease III: Interprofessional Care
Parentral Nutrition: Centeral and Peripheral Parental Nutrition
PN can be administered through two primary routes:
1. Central Parenteral Nutrition (CPN):
CPN involves delivering a high concentration of nutrients through a large vein. This is typically achieved using a Peripherally Inserted Central Catheter (PICC) or,...
Acute Coronary Syndrome IV: Interprofessional Care
Drug Delivery: Parenteral Route
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices